Genentech, Inc. (NYSE: DNA) announced that a Roche-sponsored Phase III study evaluating two different doses of Avastin(R) (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy met the primary endpoint of prolonging progression-free survival (PFS) in patients with previously untreated, advanced non-squamous, non-small cell lung cancer (NSCLC), the most common form of the disease.
In a new report in the February 15th issue of G&D, Dr. Martin McMahon (UCSF) and colleagues present a novel mouse model of non-small cell lung cancer, which will serve as a useful tool to test the efficacy of novel chemotherapeutic drug therapies in the early stages of lung tumorigenesis.
Nearly 20 percent of women who develop lung cancer have never smoked, US researchers found in a study that suggests secondhand smoke may be to blame.
Researchers at the Stanford University School of Medicine and the Northern California Cancer Center have taken the first steps toward analyzing why people who never smoked get lung cancer.
In an era when lung cancer remains the most lethal cancer, accounting for more deaths than colon, breast and prostate cancer combined — and surgery, when possible, is the most effective treatment — Mayo Clinic surgeons have proposed a system of lung surgery quality indicators for surgeons and the public as a method to demonstrate best practices for obtaining positive patient outcomes.
Mayo Clinic surgeons have proposed a system of lung surgery quality indicators for surgeons and the public as a method to demonstrate best practices for obtaining positive patient outcomes.
An analysis of nearly two dozen studies confirms the association between passive smoke in the workplace and an increased risk of lung cancer, according to a report in the American Journal of Public Health.
Antibodies that selectively bind and destroy cancer cells represent some of the most promising cancer therapy approaches being developed today.
Mutant forms of the protein EGFR are important for the development of lung cancer in a substantial proportion of individuals with this disease. However, not all individuals express the same mutant EGFR, for example, some have a mutation that affects the intracellular part of EGFR and some have a mutation that affects the extracellular part of EGFR (known as the EGFRvIII mutant).
Combination gene therapy delivered in lipid-based nanoparticles drastically reduces the number and size of human non-small cell lung cancer tumors in mice, researchers at The University of Texas M. D. Anderson Cancer Center and the University of Texas Southwestern Medical Center report in the January 15 edition of Cancer Research.